Hua Medicine (HUMDF) Stock Statistics & Valuation Metrics
Total Valuation
Hua Medicine has a market cap or net worth of $269.23M. The enterprise value is $1.29B.
- Market Cap
- $269.23M
- Enterprise Value
- $1.29B
Share Statistics
Hua Medicine has 1,056,605,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,056,605,000
- Owned by Insiders
- ―
- Owned by Institutions
- 0.38%
Financial Efficiency
Hua Medicine’s return on equity (ROE) is 1.07 and return on invested capital (ROIC) is -10.78%.
- Return on Equity (ROE)
- 1.07
- Return on Assets (ROA)
- 0.73
- Return on Invested Capital (ROIC)
- -10.78%
- Return on Capital Employed (ROCE)
- -0.11
- Revenue Per Employee
- 1.13M
- Profits Per Employee
- 2.54M
- Employee Count
- 424
- Asset Turnover
- 0.33
- Inventory Turnover
- 1.70
Valuation Ratios
The current PE Ratio of Hua Medicine is -18.06. Hua Medicine’s PEG ratio is 0.17.
- PE Ratio
- -18.06
- PS Ratio
- 2.85
- PB Ratio
- 1.85
- Price to FCF
- -49.46
- Price to Operating Cash Flow
- -57.71
- PEG Ratio
- 0.17
Income Statement
In the last 12 months, Hua Medicine had revenue of 480.18M and earned 1.08B in profits. Earnings per share was 1.09.
- Revenue
- 480.18M
- Gross Profit
- 273.10M
- Operating Income
- -141.13M
- Pretax Income
- 1.08B
- Net Income
- 1.08B
- EBITDA
- -108.66M
- Earnings Per Share (EPS)
- 1.09
Cash Flow
In the last 12 months, operating cash flow was -31.85M and capital expenditures -5.34M, giving a free cash flow of -37.19M billion.
- Operating Cash Flow
- -31.85M
- Free Cash Flow
- -37.19M
- Free Cash Flow per Share
- -0.04
Dividends & Yields
Hua Medicine pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -2.02%
- Earnings Yield
- -5.77%
Stock Price Statistics
- Beta
- 0.11
- 52-Week Price Change
- -51.74%
- 50-Day Moving Average
- 0.30
- 200-Day Moving Average
- 0.40
- Relative Strength Index (RSI)
- 44.85
- Average Volume (3m)
- 2,000
Important Dates
Hua Medicine upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 20, 2026
- Next Earnings Date
- Apr 01, 2027
- Ex-Dividend Date
- ―
Financial Position
Hua Medicine as a current ratio of 6.17, with Debt / Equity ratio of 29.97%
- Current Ratio
- 6.17
- Quick Ratio
- 5.59
- Debt to Market Cap
- 0.09
- Net Debt to EBITDA
- 7.28
- Interest Coverage Ratio
- -17.79
Taxes
In the past 12 months, Hua Medicine has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Hua Medicine EV to EBITDA ratio is -14.53, with an EV/FCF ratio of -30.14.
- EV to Sales
- 1.74
- EV to EBITDA
- -14.53
- EV to Free Cash Flow
- -30.14
- EV to Operating Cash Flow
- -35.19
Balance Sheet
Hua Medicine has $1.07B in cash and marketable securities with $354.20M in debt, giving a net cash position of $718.54M billion.
- Cash & Marketable Securities
- $1.07B
- Total Debt
- $354.20M
- Net Cash
- $718.54M
- Net Cash Per Share
- $0.68
- Tangible Book Value Per Share
- $0.97
Margins
Gross margin is 60.64%, with operating margin of -16.23%, and net profit margin of -16.46%.
- Gross Margin
- 60.64%
- Operating Margin
- -16.23%
- Pretax Margin
- -16.46%
- Net Profit Margin
- -16.46%
- EBITDA Margin
- -11.97%
- EBIT Margin
- -16.23%
Analyst Forecast
The average price target for Hua Medicine is $0.45, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $0.45
- Price Target Upside
- 61.39% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- 82.93%
- EPS Growth Forecast
- -110.17%
